Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTO-104 Safety Study in Unilateral Meniere's Disease
NCT02265393Phase 2Completed
- Sponsor
- Otonomy, Inc.
- Start
- Oct 2014
- Primary completion
- May 2016
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Otividex in Meniere's disease (MD), sponsored by Otonomy, Inc.. Started Oct 2014; status: completed.
02
Drugs
Otividex
03
Conditions
Meniere's disease (MD)
Beyond the preview
Go deeper on NCT02265393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02265393.